Bernasconi Valentina, Kristiansen Paul A, Whelan Mike, Román Raúl Gómez, Bettis Alison, Yimer Solomon Abebe, Gurry Céline, Andersen Svein R, Yeskey Debra, Mandi Henshaw, Kumar Arun, Holst Johan, Clark Carolyn, Cramer Jakob P, Røttingen John-Arne, Hatchett Richard, Saville Melanie, Norheim Gunnstein
Coalition for Epidemic Preparedness Innovation (CEPI), Marcus Thranes Gate 2, 0473, Oslo, Norway.
Coalition for Epidemic Preparedness Innovation (CEPI), NW1 2BE, London, UK.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):65-73. doi: 10.1007/s00103-019-03061-2.
Today's world is characterized by increasing population density, human mobility, urbanization, and climate and ecological change. This global dynamic has various effects, including the increased appearance of emerging infectious diseases (EIDs), which pose a growing threat to global health security.Outbreaks of EIDs, like the 2013-2016 Ebola outbreak in West Africa or the current Ebola outbreak in Democratic Republic of the Congo (DRC), have not only put populations in low- and middle-income countries (LMIC) at risk in terms of morbidity and mortality, but they also have had a significant impact on economic growth in affected regions and beyond.The Coalition for Epidemic Preparedness Innovation (CEPI) is an innovative global partnership between public, private, philanthropic, and civil society organizations that was launched as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics.CEPI is focusing on supporting candidate vaccines against the World Health Organization (WHO) Blueprint priority pathogens MERS-CoV, Nipah virus, Lassa fever virus, and Rift Valley fever virus, as well as Chikungunya virus, which is on the WHO watch list. The current vaccine portfolio contains a wide variety of technologies, ranging across recombinant viral vectors, nucleic acids, and recombinant proteins. To support and accelerate vaccine development, CEPI will also support science projects related to the development of biological standards and assays, animal models, epidemiological studies, and diagnostics, as well as build capacities for future clinical trials in risk-prone contexts.
当今世界的特点是人口密度不断增加、人口流动性增大、城市化进程加快以及气候和生态变化。这种全球动态产生了各种影响，包括新出现的传染病（EID）出现频率增加，这对全球卫生安全构成了日益严重的威胁。诸如2013 - 2016年西非埃博拉疫情或刚果民主共和国（DRC）当前的埃博拉疫情等EID疫情，不仅使低收入和中等收入国家（LMIC）的人口在发病率和死亡率方面面临风险，而且还对受影响地区及其他地区的经济增长产生了重大影响。疫情防范创新联盟（CEPI）是公共、私营、慈善和民间社会组织之间的创新性全球伙伴关系，它是在达成共识后发起的，即需要一项协调一致的国际政府间计划来研发和部署新疫苗以预防未来的疫情。CEPI专注于支持针对世界卫生组织（WHO）蓝图优先病原体中东呼吸综合征冠状病毒（MERS-CoV）、尼帕病毒、拉沙热病毒和裂谷热病毒以及列入WHO观察名单的基孔肯雅病毒的候选疫苗。目前的疫苗组合包含多种技术，涵盖重组病毒载体、核酸和重组蛋白。为了支持和加速疫苗研发，CEPI还将支持与生物标准和检测方法、动物模型、流行病学研究及诊断方法的开发相关的科研项目，并在易发生风险的环境中建设未来临床试验的能力。
